Skip to main content

Newsroom press releases

13/10/26 - 13:00

Diasorin obtained FDA approval for Human Parvovirus B19 IgM and IgG on the Liaison XL (334.34 KB)
Products Immunodiagnostic

02/10/26 - 14:22

Margherita Sacerdoti appointed Investor Relations & ESG Senior Director at Diasorin (151.77 KB)
Other

31/07/26 - 12:50

Revenue and EBITDA Supported by Strong Q2 Growth in the First Half of the Year. 2026 Guidance Confirmed. (277.39 KB)
Financial Data

19/06/26 - 15:45

Diasorin Announces FDA 510(K) Clearance and CLIA Waiver for the LIAISON NES Group A Streptococcus (GAS) Assay (174.02 KB)
Products Molecular

20/05/26 - 11:16

Diasorin Board of Directors approves the 2026-2030 Business Plan (246.32 KB)
Financial Data

19/05/26 - 19:23

Diasorin Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay (179.61 KB)
Products Molecular

08/05/26 - 17:54

Revenues and EBITDA in line with the expected quarterly revenue trend and impacted by a weak flu season. 2026 Guidance confirmed (256.38 KB)
Financial Data

04/05/26 - 17:45

Diasorin Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President (158.42 KB)
Other

29/04/26 - 15:52

Shareholders' Meeting 2026 (166.06 KB)
Other

07/04/26 - 10:05

Communication on total amount of voting rights (7 April 2026) (225.44 KB)
Other

25/03/26 - 12:04

Publication of the document for the Ordinary Shareholders' Meeting scheduled on April 29, 2026 (181.97 KB)
Financial Disclosures

20/03/26 - 17:44

Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024 (349.08 KB)
Financial Data

19/03/26 - 9:47

Diasorin signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform (234.16 KB)
Other

24/02/26 - 7:06

Diasorin introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN (154.8 KB)
Products Immunodiagnostic

03/02/26 - 12:13

Diasorin submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver (130.94 KB)
Products Molecular

29/01/26 - 7:03

Diasorin has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL (128.56 KB)
Products Immunodiagnostic

27/01/26 - 16:05

The Shareholders' meeting authorized the purchase of treasury shares, approved the amendment of art. 5 of the articles of association and authorized the cancellation of treasury shares. The Board approved the launch of the buyback plan. (120.91 KB)
Other

26/01/26 - 7:09

Diasorin signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel (131.63 KB)
Products Molecular

23/01/26 - 17:49

Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer. (108.99 KB)
Other

22/12/10 - 1:00

2011 Financial calendar (180.28 KB)
Financial Data

20/12/10 - 1:00

Dividend may be distributed in June (445.78 KB)
Financial Data

02/12/10 - 1:00

Comment on position Paper on Vitamin D (53.46 KB)
Products Immunodiagnostic

24/11/10 - 1:00

Change in share capital (46.85 KB)
Financial Data

18/11/10 - 1:00

Financial instruments to employees (48.33 KB)
Financial Data

05/11/10 - 1:00

The BoD approves Q3'10 results (414.16 KB)
Financial Data

02/11/10 - 1:00

Change in share capital (313.61 KB)
Financial Data

08/10/10 - 2:00

2010 Financial calendar update (174.1 KB)
Financial Data

30/09/10 - 2:00

Change in share capital (5.25 KB)
Financial Data

24/09/10 - 2:00

Financial instruments to employees (48.81 KB)
Financial Data

16/09/10 - 2:00

Stock options exercised by key managers (195.67 KB)
Financial Data

02/09/10 - 2:00

Financial instruments to employees (24.27 KB)
Financial Data

06/08/10 - 2:00

The BoD approves H1'10 results (287.11 KB)
Financial Data

07/07/10 - 2:00

Agreement with Meridian Inc. (182.7 KB)
Acquisition / Partnership

06/07/10 - 2:00

2010 Financial calendar update (174.1 KB)
Financial Data

02/07/10 - 2:00

Financial instruments to employees (24.37 KB)
Financial Data

01/06/10 - 2:00

Acquisition of MUREX product line (102.6 KB)
Acquisition / Partnership

14/05/10 - 2:00

The BoD approves Q1'10 results (254.05 KB)
Financial Data

27/04/10 - 2:00

Approval of statutory financial statements (182.99 KB)
Financial Data

20/04/10 - 2:00

2010 Financial calendar update (168.23 KB)
Financial Data

14/04/10 - 2:00

Postponement of the term for lists of members of the Board of Auditors (40.34 KB)
Financial Data

09/04/10 - 2:00

China approves new prenatal screening product line on LIAISON (141.08 KB)
Products Immunodiagnostic

02/04/10 - 2:00

Financial instruments to employees (27.79 KB)
Financial Data

22/03/10 - 1:00

The BoD approves FY 2009 results (306.02 KB)
Financial Data

10/03/10 - 1:00

Acquisition of MUREX product line (45.5 KB)
Acquisition / Partnership

01/03/10 - 1:00

2010 Financial calendar update (192.49 KB)
Financial Data

12/02/10 - 1:00

The BoD approves Q4'09 results (213.8 KB)
Financial Data

18/01/10 - 1:00

2010 Financial calendar (103 KB)
Financial Data